TRAMP-C2可移植前列腺癌动物模型的建立及初步应用  

Establishment and application of transplantable TRAMP-C2 prostate cancer mice model

作　　者：厉将斌[1] 李洪燕[2] 李学松[3] 陈晓光[2] 郭应禄[3] 

机构地区：[1]北京大学光华管理学院卫生经济与管理系,北京100871 [2]中国医学科学院中国协和医科大学药物研究所 [3]北京大学第一医院泌尿外科

出　　处：《北京中医药大学学报》2008年第3期189-191,195,I0002,共5页Journal of Beijing University of Traditional Chinese Medicine

摘　　要：目的建立一个可移植前列腺癌动物模型，并用于评价药物的抗肿瘤作用。方法将转基因小鼠前列腺癌细胞株TRAMP-C2接种入C57BL／6N小鼠，体内传代至其生物学特性趋于稳定，观察环磷酰胺（CTX）、中药紫龙金和自拟中药方对模型肿瘤的抑制作用。结果TRAMP—C2接种入C57BL／6N小鼠后，肿瘤开始生长，体内传代4代后基本稳定，皮下接种约1×10^7的细胞，经4周肿瘤可达N2-3g；CTX、紫龙金和自拟中药方对模型肿瘤的生长抑制率分别为83．23％、29．58％和36．03％。结论TRAMP—C2可移植前列腺癌小鼠模型是一个新的动物模型，并可作为抗前列腺癌药物研究之用。Objective To establish an implantable animal model of prostate cancer, and to app!y it to evaluate the anti-tumor activity of medicine. Methods Transgenic adenocarcinoma mouse prostate cell （TRAMP-C2） suspensions were implanted to C57BL/6N mice subcutaneously at oxter. TRAMP-C2 was went down to the future generates in mice until the biological features were stable. The anti-cancer activity of cyclophosphamide （CTX）, TCM recipe Zilongjin and TCM complex prescription were tested on this mice model. Results The biological features were stable after four generations. The weight of tumor reached 2-3g four weeks after hypodermic inoculation of 1 ×10^7 cells. The growth inhibiting ratios of tumor were 83. 23% 29. 58% and 36. 03% for CTX, Zilongiin and TCM complex prescription, respectively. Conclusion The establishment of TRAMP-C2 implantable mice model provided a new model for the study of prostate cancer medicine treatment.

关 键 词：前列腺癌 动物模型 TRAMP—C2 中药 小鼠 

分 类 号：R285.5[医药卫生—中药学]